Skip to content
MISTMilestone Pharmaceuticals Inc.

Earnings

When Milestone Pharmaceuticals Inc. reports, what it reported each quarter, and how the stock took the results.

35 quarters. Mar 31, 2018 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 19, before the open

Fri, Mar 19, 2027in 122 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 10 – Apr 1

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Net income
-$17.41M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$963.00KNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 13, 2026, before the openThe release
    Revenue
    $963.00K
    —
    Net income
    -$25.80M
    N/M
    EPS
    -$0.18
    N/M
  2. Q2 2026Aug 12, 2026, before the openThe release11.0%by the close of Aug 12
    Revenue
    $559.00K
    —
    Net income
    -$28.61M
    N/M
    EPS
    -$0.21
    N/M
  3. Q1 2026May 13, 2026, before the openThe release9.5%by the close of May 13
    Revenue
    $238.00K
    —
    Net income
    -$26.07M
    N/M
    EPS
    -$0.20
    N/M
  4. Q4 2025Mar 20, 2026, before the openThe release19.7%by the close of Mar 20
    Revenue
    —
    —
    Net income
    -$17.41M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 13, 2026 · pre-marketNov 13, 202644 d10-Q$963.00K—-$0.18—
Q2 2026Jun 30, 2026Aug 12, 2026 · pre-marketAug 12, 202643 d10-Q$559.00K—-$0.2111.0%
Q1 2026Mar 31, 2026May 13, 2026 · pre-marketMay 13, 202643 d10-Q$238.00K—-$0.209.5%
FY 2025
Q4 2025derivedDec 31, 2025Mar 20, 2026 · pre-marketMar 20, 202679 d10-K———19.7%
Q3 2025Sep 30, 2025Nov 12, 2025 · pre-marketNov 12, 202543 d10-Q$0.00—-$0.12+0.5%
Q2 2025Jun 30, 2025Aug 12, 2025 · pre-marketAug 12, 202543 d10-Q$0.00—-$0.20+6.4%
Q1 2025Mar 31, 2025May 14, 2025 · pre-marketMay 14, 202544 d10-Q$0.00—-$0.312.1%
FY 2024
Q4 2024derivedDec 31, 2024Mar 13, 2025 · pre-marketMar 13, 202572 d10-K———+4.4%
Q3 2024Sep 30, 2024Nov 12, 2024 · pre-marketNov 12, 202443 d10-Q——-$0.143.6%
Q2 2024Jun 30, 2024Aug 8, 2024 · after-hoursAug 8, 202439 d10-Q——-$0.14+1.4%
Q1 2024Mar 31, 2024May 13, 2024 · pre-marketMay 13, 202443 d10-Q——-$0.21—
Earlier years, FY 2018 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 13, 2026126504
10-QAug 12, 2026094435
10-QMay 13, 2026059752
10-KMar 20, 2026032415
10-QNov 12, 2025109689
10-QAug 12, 2025011141
10-QMay 14, 2025007648
10-KMar 13, 2025002849
10-QNov 12, 2024015147
10-QAug 8, 2024011603

Provenance

ProvenanceData status and checks

Milestone Pharmaceuticals Inc. · CIK 1408443 · Engraved from SEC EDGAR